• Alligator Bioscience’s board proposes a 1-for-1,000 reverse ordinary share split at the November 27, 2026, extraordinary general meeting.
• A proposed 152-share equalization issue would bring ordinary shares to 3,568,107,000 before consolidation reduces the total to 3,568,107.
• The split would increase quota value from SEK 0.005 to SEK 5; split-adjusted trading is provisionally scheduled for December 8, 2026.
• Shareholders will also vote on authorizing warrant issues to fulfill obligations under the July 2026 loan agreement with Fenja Capital II.
• Proposed board elections and remuneration decisions depend on a nomination committee being constituted to prepare proposals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alligator Bioscience AB published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.